Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Eleonora CesariAlessandra CiucciMarco PieraccioliCinzia CaggianoCamilla NeroDavide BonvissutoFrancesca SillanoMarianna ButtarelliAlessia PiermatteiMatteo LoverroFloriana CamardaViviana GrecoMaria De BonisAngelo MinucciDaniela GalloAndrea UrbaniGiuseppe VizzielliGiovanni ScambiaClaudio SettePublished in: Journal of experimental & clinical cancer research : CR (2023)
CDK12 and CDK13 represent valuable therapeutic targets for HGSOC. We uncovered a wide spectrum of CDK12/13 targets as potential therapeutic vulnerabilities for HGSOC. Moreover, our study indicates that CDK12/13 inhibition enhances the efficacy of approved drugs that are already in use for HGSOC or other human cancers.